Clinical Scorecard: Delays in Hematology Consultations and Non-Hematology Referrals in Blood Cancer Diagnosis: Insights from a Comprehensive National Survey in Australia

At a Glance

Key Highlights

• Blood cancers are the third most common cancer in Australia, with over 150,000 individuals affected.
• Delays in diagnosis are linked to fewer treatment options and increased morbidity risks.
• Patient and health system factors contribute to diagnostic delays, including multiple GP visits.
• Delays beyond 2-3 months are associated with advanced disease features and complications.
• The economic cost of blood cancer in Australia is projected to reach $71.9 billion by 2035.

Guideline-Based Recommendations

Diagnosis

• Timely referral from GPs to hematologists is crucial for suspected blood cancer cases.

Management

• Optimal Care Pathways recommend a 2-4 week timeframe from GP presentation to first hematologist consult.

Monitoring & Follow-up

• Regular assessment of diagnostic time intervals and patient outcomes is necessary.

Risks

• Delayed diagnosis can lead to advanced disease, organ damage, and higher complication rates.

Patient & Prescribing Data

Patients with leukaemia, lymphoma, multiple myeloma, MDS, and MPN diagnosed between 2018 and 2022.

Delays in diagnosis are associated with increased healthcare costs and decreased quality of life.

Clinical Best Practices

• Encourage prompt help-seeking behaviors among patients presenting with symptoms.
• Educate healthcare professionals on recognizing symptoms of blood cancers.
• Implement strategies to reduce waiting times for specialist appointments.

References

• Blood Cancer Taskforce
• Australian Optimal Care Pathways
• NICE Guidelines on Suspected Cancer